In a video interview with Urology Times, Julie Graff, M.D., is one of two experts who discuss considerations that factor into which androgen receptor inhibitor is selected as treatment for nonmetastatic castration-resistant prostate cancer.

OHSU is among seven universities/foundations to receive funding from Cambia Health Foundation to develop innovative strategies that will increase the diversity of students entering and completing post-secondary programs in health care.

Henry Hernandez 19, who is a barista at an area Starbucks, teamed up with company leadership to launch a state-wide toy drive, benefiting OHSU Doernbecher Children’s Hospital and local Make-A-Wish kids.

The project includes neuroscientists at the University of Washington, Oregon Health & Science University, and other institutions.

Methamphetamine use has gone up 180% across the United States over the last few years, according to the National Institute on Drug Abuse; Todd Korthuis, M.D., says overdoses also are up: “The potency of methamphetamine has increased, and the purity of methamphetamine has increased."

An editorial authored by Danny Jacobs, M.D., is referenced in an article about antibiotic therapy for appendicitis.

An evidence review led by Roger Chou, M.D., prompts the U.S. Preventive Services Task Force to conclude the evidence for weighing the balance of benefits and harms of screening adults aged 40 years or older for primary open-angle glaucoma is currently inadequate.

Ben Hoffman, M.D. comments on a new booster safety seat law intended to help keep children safe when traveling in cars: “We’ve been waiting 20 years for a side-impact standard, so pushing that to completion is going to be huge. We can’t afford to wait another 20 years.

A report on the availability of Moderna and Johnson & Johnson booster doses at various locations statewide, including OHSU.

Article features comments from Zahi Mitri, M.D., regarding long-term impacts of the drug herceptin on treating HER-2 positive breast cancer: “Patients can actually be confident that their treatment can help them really beat this cancer because this study follows patients for not one or two years, but up to a 10-year follow-up for most patients.”